16078-63-0

Usage

Uses

Used in Medicinal Chemistry:
Ethyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate is used as a chemical compound in medicinal chemistry for its potential pharmacological activities. Its pyrazole structure and functional groups contribute to its diverse applications in the development of new drugs.
Used in Anti-inflammatory Applications:
Ethyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate is used as an anti-inflammatory agent due to its ability to modulate inflammatory pathways and reduce inflammation-related symptoms.
Used in Antiviral Applications:
Ethyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate is used as an antiviral agent, potentially inhibiting viral replication and reducing the severity of viral infections.
Used in Anticancer Applications:
Ethyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate is used as an anticancer agent, exhibiting potential inhibitory effects on tumor growth and progression. Its pyrazole structure and functional groups may contribute to its activity against various types of cancer.
Used in Drug Development:
Ethyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate is used in drug development as a promising candidate for the synthesis of new pharmaceutical compounds with potential therapeutic benefits in various diseases and conditions. Its unique structure and pharmacological properties make it an interesting target for further research and exploration.

Upstream product

• 100-63-0 phenylhydrazine 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 591-50-4 iodobenzene 
• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 
• 588-64-7 benzaldehyde phenylhydrazone 

Downstream Products

• 122800-03-7 3-(4-Fluoro-2-nitro-phenylamino)-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1003578-23-1 ethyl 3-(bis(tert-butoxycarbonyl)amino)-1-phenyl-1H-pyrazole-4-carboxylate 
• 132680-66-1 2-phenyl-2H,4H-pyrazolo<4,3-b>pyrrolizine 
• 132680-72-9 4-oxo-2-phenyl-2H,4H-pyrazolo<4,3-b>pyrrolizine 
• 132680-71-8 1-phenyl-3-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylic acid 
• 132680-27-4 1-phenyl-3-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylic acid pyrrolidinamide 
• 865868-84-4 ethyl 1-phenyl-3-(phenylamino)-1H-pyrazole-4-carboxylate 
• 865868-13-9 ethyl 3-[(1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylate 
• 865868-86-6 ethyl 3-{[(trans-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylate 
• 923010-31-5 3-amino-1-phenyl-1H-pyrazole-4-carboxylic acid 
• 1335105-18-4 3-acetylamino-1-phenyl-1H-pyrazole-4-carboxylic acid ethylester 
• 1383677-77-7 ethyl 3-bromo-1-phenyl-1H-pyrazole-4-carboxylate 
• 865868-88-8 1,1-dimethylethyl 4-({4-[(ethyloxy)carbonyl]-1-phenyl-1H-pyrazol-3-yl}amino)-1-piperidinecarboxylate 
• 865868-99-1 ethyl 1-phenyl-3-[(2-pyrazinylmethyl)amino]-1H-pyrazole-4-carboxylate 

Relevant academic research and scientific papers

HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

A Michael Equilibration Model to Control Site Selectivity in the Condensation toward Aminopyrazoles

A Michael equilibration model is presented to provide for site-selective pyrazole condensations between alkoxyacrylonitriles and hydrazines. Both pyrazole isomers were accessed with high selectivity by employment of kinetically or thermodynamically controlled conditions. Substrate scope and identification of Michael intermediates, as well as competitive pathways, support the presented mechanistic proposal. Sandmeyer derivatization provided site-selective access to fully substituted pyrazoles.

Application of Ullmann and Ullmann-Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation

Ullmann-type reactions are becoming a major tool in medicinal chemistry. In this article, we describe the use of these Copper-catalyzed reactions with various precursors, acyl-heteroarylamines or pyrazoles of interest for pharmacomodulation. To the medicinal chemist they offer new, usually untapped disconnection approaches to compounds of interest. They thus open the way to new original analogues of bioactive compounds possibly not patented, from common building-blocks. They also allow C to N bioisosteric replacements, which sometimes are synthetically challenging. We report for the first time the critical effect of acetylamino substituents on the regioselective arylation of unsymmetrical pyrazoles that are useful for medicinal chemists. Finally, we have applied this strategy to the design of novel AT1 receptor antagonists. Though this family has been extensively investigated in the past 30 years, N-arylation and C to N replacement made possible by Ullmann chemistry, can produce original antagonists.

4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS

Novel antiviral compounds of Formula (I) : wherein: A represents hydroxy; R1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, C1-6alkyl or -C5-9cycloalkyl, each of which may be optionally su